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Abstract
Peptide dendrimers are a class of molecules that exhibit a large array of biological effects including antiviral activity. In this
report, we analyzed the antiviral activity of the peptide-derivatized SB105-A10 dendrimer, which is a tetra-branched
dendrimer synthetized on a lysine core, in activated peripheral blood mononuclear cells (PBMCs) that were challenged with
reference and wild-type human immunodeficiency virus type 1 (HIV-1) strains. SB105-A10 inhibited infections by HIV-1 X4
and R5 strains, interfering with the early phases of the viral replication cycle. SB105-A10 targets heparan sulfate
proteoglycans (HSPGs) and, importantly, the surface plasmon resonance (SPR) assay revealed that SB105-A10 strongly binds
gp41 and gp120, most likely preventing HIV-1 attachment/entry through multiple mechanisms. Interestingly, the antiviral
activity of SB105-A10 was also detectable in an organ-like structure of human cervicovaginal tissue, in which SB105-A10
inhibited the HIV-1ada R5 strain infection without altering the tissue viability. These results demonstrated the strong antiviral
activity of SB105-A10 and suggest a potential microbicide use of this dendrimer to prevent the heterosexual transmission of
HIV-1.
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Introduction
HIV induces a life-long infection, which, if untreated, progres-
sively evolves to acquired immunodeficiency syndrome (AIDS)
with the ultimate death of the infected patients [1]. The World
Health Organization has globally estimated that 34 million people
were living with HIV-1 at the end of 2011, a year in which 2.5
million of people were newly infected and 1.7 million individuals
died with AIDS-related diseases [2]. HIV epidemics may produce
20–60 million new infections during the next 15–20 years,
particularly in the developing world [3]. To tackle the HIV
infection, two traditional approaches, represented by the pharma-
cological treatment and prophylaxis measures, have been
proposed [3,4]. Combined antiretroviral therapy (cART) has
dramatically changed the evolution of HIV disease but, unfortu-
nately, has not been able to eradicate the HIV infection [5–8].
However, the treatment of HIV positive patients with cART
suppresses viral replication with a consequent decrease in the viral
load that can limit HIV transmission and reduce the number of
new infections [9]. Preventive socio-behavioural measures, the
medical treatment of other sexually transmitted diseases and
immunological strategies have also been proposed in an attempt to
combat the spread of HIV infections [3,10,11]. In particular,
several vaccines have been evaluated in trials, but none have been
able to induce a sterilizing immune response that prevents HIV
transmission and infections in the population [12]. The absence of
a broadly protective vaccine against the various HIV subtypes
indicates that the development of alternative pharmacological
approaches to HIV infection prophylaxis may be considered a
major avenue for controlling HIV transmission. Because approx-
imately 85% of HIV cases originate from sexual transmission [13]
and because heterosexual contact represents the major route of
infection [14], the development of pharmacological topical
treatments, that employ so-called microbicides, might be crucial
to prevent or reduce the transmission of HIV at the level of the
genital mucosa [15–17]. Mathematical models have predicted that
60%-effective microbicides with 20% coverage could prevent 2.5
millions new infections within three years [18,19], suggesting that
the identification of novel microbicides might play an important
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role in HIV infection control, pending the development of a
functional vaccine.
The viral replication cycle offers several targets for microbicide
development [20], although both the inhibition of entry and
retrotranscription processes are currently considered the most
promising targets [15]. The strategies to block HIV entry into cells
are mainly focused on interference of viral capture, CD4
engagement inhibition, co-receptor binding and gp41 rearrange-
ment resulting in the use of many microbicides, such as
polyanions, lectins, monoclonal antibodies, CXCR4, CCR5,
CD4 and gp120 binding factors and gp41-fusion inhibitors
[9,21]. In addition, some non-nucleoside (NNRTIs) and nucleo-
side retrotranscriptase inhibitors (NRTIs) may also be considered
microbicides [22]. Recently, a tenofovir (TDF) gel that was used
during intercourse by women in the Centre for the AIDS
Programme of Research in South Africa (CAPRISA) 004 study
[23] yielded effective results; however, in the VOICE trial, the use
of a daily-administered TDF gel failed to reproduce these data
[24]. Interestingly, similarly controversial results were observed
with oral TDF or TDF/FTC once-daily treatments in three
separate studies [25–27], most likely, caused by the different levels
of patient adherence to the tested therapy [28,29]. There are
approximately 50 candidate microbicides currently in develop-
ment, and some of these compounds are in trial phases 2 and 3
[21]. Unfortunately, many molecules have not passed the
preclinical safety and/or efficacy tests or have failed when
clinically tested. An interesting class of molecules with antiviral
activity is represented by dendrimers [30]. Dendrimers are highly
branched macromolecules that possess a poly-functional core
associated with multiple functional groups on the surface layer
[30–31]. Dendrimer-based molecules have been described as
yielding many potential therapeutic applications and, most
importantly, as exhibiting antiviral and antibacterial activities
[32,33]. Notably, dendrimers display polyvalent viral inhibition
using multiple repeat domains on a single molecule that can
induce a derangement of virus/cell surface and interaction.
Sulfonated polylysine dendrimers have shown anti-HSV and
antiretroviral activities; indeed, the SPL7013 compound, which is
the most active of these dendrimers, has been proposed as a
candidate topical microbicide. Interestingly, SPL7013 has exhib-
ited anti-HIV activities in vitro [34,35], ex vivo [36] and in a
macaque challenge study [37].
In the present study, we analyzed the anti-HIV activity of the
SB105-A10 dendrimer synthetized on a lysine core, which exposed
four 9-mer peptide chains [38] that have been previously
demonstrated to block viral attachment and entry of different
viruses [39–41]. In this investigation, we tested the antiretroviral
activity of the SB105-A10 dendrimer on the replication of HIV-1
X4 and R5 strains to determine whether this molecule may be
considered a novel compound with anti-HIV properties.
Materials and Methods
Cell cultures
The study is in accordance with the provisions of the
Declaration of Helsinki and St Orsola-Malpighi Hospital, Bolo-
gna, Italy. Peripheral blood samples were collected from healthy
blood donors during their routine laboratory analysis at Blood
Bank, S.Orsola-Malpighi Hospital, Bologna in according to the
rules established by Italian Law (Legislative Decree 03-03-2005,
published in G.U. n. 85, 13.04.2005). No approval from Ethical
Committee was requested because all blood samples were
anonymous and could not related to any blood donor. The
PBMCs were separated from peripheral blood samples using a
Ficoll gradient (Ficoll-Histopaque, Pharmacia, Uppsala, Sweden)
and were seeded in RPMI1640 plus 10% FCS and 2 mM L-
glutamine at 56105 cells/ml. The PBMCs were activated by PHA
(5 mg/ml; Sigma, St Louis, MO, USA) plus IL-2 (10 U/ml; Pierce,
Rockford, IL, USA) treatment for three days. The medium was
replaced every three days with fresh medium
(RPMI1640+10%FCS, 2 mM L-glutamine and 10 U/ml IL-2).
Virus stocks
Sixteen HIV-1 X4 or R5 strains were selected for the
experiments. HIV-1IIIb and HIV-1ada are classical laboratory X4
and R5 strains, respectively. Six additional HIV-1 reference strains
(ARV-2, RU132, SE9173, MP535, CBL-4 and BaL) were
obtained from NIBSC (NIBSC, London, UK), whereas eight
HIV-1 isolates were achieved from naı¨ve or cART-treated HIV
positive subjects (Table 1). Reference HIV strain stocks were
prepared in C8166 cells (HIV-1IIIb) or in activated PBMCs [42]
whereas the HIV-1 primary viral isolates from eight HIV-infected
subjects were obtained using a co-culture technique, as described
previously [42]. All of the viral stocks were titrated using an HIV-1
gag p24 antigen ELISA kit (Biomerieux, Marcy L9Etoile, France)
at 1000 ng/ml of the HIV-1 gag p24 protein. Viral tropism of
HIV-1 primary viral isolates from eight HIV-infected subjects was
evaluated by genotypic methods as previously described [43].
Dendrimers
SB105-A10 ([H-ASLRVRIKK]4 Lys2-Lys-b-Ala-OH;
Figure 1) and SB104 ([H-NKKIRVRL]4-Lys2-Lys-b-Ala-OH)
dendrimers (Spider Biotech, Turin, Italy) were synthesized as
described previously [39,40]. The lyophilized dendrimers with a
purity of .95%, as determined by HPLC-UV (Waters, Milford,
MA, USA), were solubilized (1 mg/ml) in phosphate buffered
saline (PBS) and stored at 280uC until use. FITC-conjugated
SB105-A10 (Polypeptide Laboratories France, Strasbourg, France)
was solubilized in PBS at 0.5 mg/ml and stored at 220uC until
use. A labeled tetrameric peptide, which bore a biotin moiety
Table 1. HIV-1 strains.
HIV-1 strains HIV-1 subtype HIV-1 tropism
HIV-1IIIb B X4
HIV-1Ada B R5
HIV-1ARV-2 B R5/X4
HIV-1RU132 G R5
HIV-1SE9173 J R5
HIV-1MP535 K R5
HIV-1CBL-4 D X4
HIV-1BaL B R5
HIV-1VNBR5N* B R5
HIV-1AMBR5N* B R5
HIV-1ACBR5N* B R5
HIV-1MCBR5N* B R5
HIV-1CLBX4T** B X4
HIV-1ARR564T** B R5/X4
HIV-1FLR564T** B R5/X4
HIV-1CSX4T** B X4
*HIV-1 isolated from HIV-1 positive naive patients.
**HIV-1 isolated from cART-treated HIV-1 positive patients.
doi:10.1371/journal.pone.0076482.t001
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linked to the lysine core by a 30-atom pegylated spacer, called
SB105-A10-PEG-biotin (Polypeptide Laboratories), had a purity
of .95% and was employed in surface plasmon resonance (SPR)
analysis.
HIV infection and dendrimer treatment
The HIV-1 strains (100 pg/ml of HIV-1 gag p24) were pre-
incubated for 1 hour at 37uC with scalar concentrations (0, 0.1, 1,
5, 10 and 20 mg/ml) of SB105-A10 or SB104, and then added to
activated PBMCs that were adjusted to a final density of 16106
cells/ml for 2 hours at 37uC. After four washes in PBS, the cells
were seeded at 56105 PBMCs/ml into fresh medium with scalar
concentrations of SB105-A10 or SB104. One-half of the medium
was replaced with fresh medium plus dendrimers at day 4 post-
infection (pi). The HIV-1 gag p24 content was determined at days
4 and 7 pi in culture supernatants, using HIV-1 p24 antigen
ELISA kit (Biomerieux). The cell viability was evaluated by the
Trypan Blue exclusion technique in the presence of scalar
concentrations of the dendrimers.
Attachment assays
Four different assays were performed.
In the pre-attachment assay, activated PBMCs (16106 cells/ml)
were incubated with SB105-A10 (20 mg/ml; 4.2 mM) for 1 hour at
4uC. After removal of the compound by PBS washes, either HlV-
1lllb or HlV-1ada (100 pg/ml of HIV-1 p24) was added to activated
PBMCs (16106 cells/ml) and incubated for 1 hour at 4uC. After
two washes with PBS, the activated PBMCs were seeded at 56105
cells/ml into fresh medium containing the dendrimer (20 mg/ml),
and the temperature was changed to 37uC. As control, the
activated PBMCs were treated with the same protocol without
dendrimer. The HIV-1 gag p24 content was determined at day 4
in the culture supernatants, using an HIV-1 p24 antigen ELISA kit
(Biomerieux).
In the post-attachment assay, the activated PBMCs (16106
cells/ml) were incubated either with HlV-1lllb or HlV-1ada
(100 pg/ml of HIV-1 p24) for 1 hour at 37uC. After the PBS
washes to remove the unbound virus, the activated PBMCs were
seeded at 56105 cells/ml and incubated at 37uC into fresh
medium containing SB105-A10 (20 mg/ml; 4.2 mM). As control,
the activated PBMCs were treated with the same protocol without
dendrimer. The HIV-1 gag p24 content in the culture superna-
tants was determined at day 4 using an HIV-1 p24 antigen ELISA
kit (Biomerieux).
In the attachment assay, SB105-A10 (20 mg/ml; 4.2 mM) was
pre-incubated with either HlV-1lllb or HlV-1ada (100 pg/ml of
HIV-1 p24) for 1 hour at 4uC. The mixture was added to the
activated PBMCs (16106 cells/ml) and incubated for 1 hour at
4uC to ensure HIV-1 attachment but not entry. After the PBS
washes, activated PBMCs were sedeed at 56105 cells/ml into a
medium containing SB105-A10 (20 mg/ml; 4.2 mM) and shifted to
a temperature of 37uC. As control, the activated PBMCs were
treated with the same protocol without dendrimer. The HIV-1 gag
p24 protein content in the culture supernatants was determined at
day 4 using an HIV-1 p24 antigen ELISA kit (Biomerieux).
In the dilution experiments, SB105-A10 (20 mg/ml; 4.2 mM)
was pre-incubated with either HlV-1lllb or HlV-1ada (100 pg/ml of
HIV-1 p24) for 1 hour at 37uC. The sample volume was diluted
50-fold with RPMI 1640 to reduce the free peptide concentrations
to a level below that at which the HIV replication would have
been significantly inhibited. The diluted mixture was added to the
activated PBMCs (16106 cells/ml) and incubated for 2 hours at
37uC. After two washes, the cells were seeded at 56105 cells/ml
into fresh medium, and HIV-1 p24 protein content in the culture
supernatants was determined at day 4 using an HIV-1 p24 antigen
ELISA kit (Biomerieux). As control, activated PBMCs were treated
with the same protocol without dendrimer.
Cell-binding assay for the FITC-SB105-A10 peptide
Activated PBMCs (56106/ml) were incubated for 1 h at 4uC in
PBS containing 2% FBS, with increasing concentrations of the
FITC-SB105-A10 dendrimer (0, 2.5, 25, 100 and 250 mg/ml). At
the end of the incubation period, the cells were extensively washed
with PBS, and the activated PBMCs were analyzed by FACScan
flow cytometry (Becton-Dickinson, Palo Alto CA). In parallel
experiments, the activated PBMCs were pre-incubated with
FITC-SB105-A10 dendrimer (25 mg/ml; 5.3 mM) and then
washed with PBS containing 2M NaCl, which is a treatment that
removes cationic polypeptides from the cell surface HSPGs [44].
Alternatively, the activated PBMCs were either incubated with
heparinase III (40 mU/ml; Sigma, St Louis, MO, USA) in 20 mM
TrisHCl pH 7.5, 0.1 mg/ml BSA and 4 mM CaCl2 for 2 h at
37uC or left untreated prior to being assayed for binding between
the activated PBMCs and 25 mg/ml (5.3 mM) of FITC-SB105-A10
dendrimer. The samples were analyzed by FACScan flow
cytometry.
Surface plasmon resonance (SPR) assay
SPR measurements were performed on a BIAcore X100
instrument (GE-Healthcare, Milwaukee, WI), using a research-
grade SA streptavidin-precoated sensorchip. To study the SB105-
A10 interaction with the HIV-1 glycosilated recombinant gp41
ectodomain (amino acids 546-682; NIBSC, UK) and the full-
lenght recombinant gp120 glycoprotein (NIBSC), biotinylated
SB105-A10 [10 mg/ml in 10 mM HEPES buffer pH 7.4 contain-
ing 150 mM NaCl, 3 mM EDTA, 0.005% and surfactant P20
(HBS-EP)] was injected onto the SA sensorchip, allowing the
immobilization of 560 resonance units (RU) equal to 0,12 pmol/
Figure 1. Structure of SB105-A10 and SB104 dendrimers. The
general structure of peptide is indicated. These dendrimers were
synthesized by the addition of four identical short peptide chains to a
tetrameric lysine central core. The aminoacid sequence of four peptide
chains in SB105-A10 and SB104 is also shown.
doi:10.1371/journal.pone.0076482.g001
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mm2 of the tetrameric peptide. A sensorchip coated with
streptavidin alone was used for blank subtraction and to evaluate
the non-specific binding. Increasing concentrations of gp41 and
gp120 in HBS-EP buffer were allowed to associate with the
SB105-A10- or streptavidin-coated surfaces for 3 min and then
washed for 10 min to allow their dissociation. As a further control
of specificity, bovine serum albumin (BSA) and the glycosylated
lectin from Sambucus nigra (SNA) (Vector Lab, Burlingame, CA,
USA) were injected on the SB105-A10 surface under the same
experimental conditions described above. After every run, the
sensorchip was regenerated by the injection of 2 M NaCl. The
steady-state affinity was calculated by the Biacore X100 evaluation
software from the RU values of HIV proteins that were bound at
equilibrium to the SB105-A10 surface.
Cervicovaginal tissue model
The EpiVaginal Tissue Model (VLC-100FT; MatTek Corp.,
Ashland, MA, USA) was kept in a 24-well plate containing a
proprietary growth medium, according to the manufacturer’s
indications. This in vitro-reconstituted, full thickness vaginal tissue
model was formed by a complete, stratified vaginal–ectocervical
epithelial layer mixed with Langerhans cells and with an
additional fibroblast-containing lamina propria. Each EpiVagi-
nalTM tissue-containing well was treated with 100 ml of topically
applied PBS (negative control), PBS containing HIV-1ada (25 ng
p24/tissue) or PBS containing HIV-1ada plus the SB105-A10
dendrimer (2 or 10 mg/tissue) for 24 hours. The apical surface of
each tissue was washed twice with PBS, and either 50 ml of PBS or
PBS plus the SB105-A10 dendrimer (1 or 5 mg/tissue) was added
at day 1. The underlying media (2 ml/tissue) was changed every
other day, and the tissues were harvested at day 4 pi. The vaginal
tissues and culture supernatants were collected for isolation of the
HIV-1 DNA. The total DNA was extracted and purified from the
vaginal tissues using the DNA easy kit (Qiagen, Hilden, Germany).
The HIV-1 DNA content was determined by SYBR Green-based
quantitative real-time PCR and normalized as already described
[45]. The oligonucleotide pairs were gag and pol gene specific
primers previously indicated [45,46].
Evaluation of the irritation potential of SB105-A10 on
EpiVaginal system
The cytotoxicity of SB105-A10 on the mucous membranes was
assessed using the EpiVaginal system and an MTT ET-50 tissue
viability assay, followed by analysis of the lactate dehydrogenase
(LDH) levels, according to the manufacturer’s instructions. SB105-
A10 (100 mg/ml; 21 mM) was added to the cell culture insert on
top of the EpiVaginal tissue samples and incubated for 1, 4, or
18 hours in duplicate. At the end of the incubation at 37uC, any
liquid on top of the EpiVaginal tissue was decanted, and the inserts
were gently rinsed with PBS to remove the residual material.
Subsequently, the tissues were processed according to the MTT kit
protocol (MatTek Corporation) and read using an ELISA plate
reader at a wavelength of 570 nm. Tissues, incubated with
ultrapure water, were employed as negative controls. Triton X-
100 (1%) was used as the positive control. The ET50 is the time
required to reduce the tissue viability to 50% and was determined
using the Prism software (GraphPad Software, San Diego, CA). To
analyze the release of LDH from the treated EpiVaginal tissues
into the culture medium, an LDH cytotoxicity detection kit
(TaKaRa Bio Inc, Japan) was utilized according to the manufac-
turer’s protocol.
To evaluate the inflammatory response, the EpiVaginal tissues
were treated with the dendrimeric peptide SB105-A10 (100 mg/
ml; 21 mM) for different exposure times of 1, 4, and 18 h, as
reported previously. After incubation, the concentration of
interleukin-1 alpha (IL-1a) in the culture medium was measured
using an IL-1a ELISA kit (Bender Medsystem, Wien, Austria).
The concentration of IL-1a was calculated by interpolation of a
standard calibration curve. IL-1a was chosen as a marker of pro-
inflammatory activity as suggested by the technical data sheet from
MatTek Corporation.
Statistical analysis
The results were expressed as the means 6 standard deviations
(SD) of at least three separate experiments performed in duplicate.
A two-tailed Student’s test was used for the statistical comparison.
Results
SB105-A10 inhibits HlV-1IIIb and HlV-1ada replication in
activated PBMCs
In the first set of experiments, the antiviral effects of SB105-A10
on the HIV-1 replication were evaluated. SB105-A10 was
challenged with the HIV-1 X4 and R5 laboratory strains,
represented by HIV-1IIIb and HlV-1ada, respectively. Scalar
concentrations of SB105-A10 (0, 0.1, 1, 5, 10 and 20 mg/ml)
were incubated with either HIV-1IIIb or HlV-1ada (100 pg of p24/
ml) and, after 2 hours at 37uC, this mixture was added to the
activated PBMCs. The HIV-1 p24 protein content was evaluated
in the culture supernatants at days 4 and 7 post-infection (pi). A
significant decrease in the p24 protein was detected in a SB105-
A10 concentration-dependent way. The determination of the IC50
yielded values of 1.42 mg/ml (0.3 mM) and 1.28 mg/ml (0.27 mM)
at day 7 pi in the samples that were infected with HIV-1IIIb and
HlV-1ada, respectively (Figure 2A).
When the same experimental protocol was performed by
substituting SB105-A10 with SB104, which is a dendrimer
possessing a same net positive charge (four basic amino acids)
but a different sequence (NKKIRVRL) in the external peptide
chains, no significant decrease in the levels of the p24 protein
amount was observed (Figure 2B). To rule out a relationship
between the HIV-1 p24 decrease and the SB105-A10-related
cytotoxicity, scalar concentrations of SB105-A10 (0.1, 1, 5, 10, 20
and 50 mg/ml) were assayed on PBMCs, and the cell viability was
analyzed by the trypan blue exclusion technique. The viability of
both SB105-A10- and SB104-treated cells was not significantly
affected when compared with the untreated cell cultures
(Figure 2C-D) and yielded a CC50 value .50 mg/ml
(.10.5 mM).
SB105-A10 exhibits antiretroviral activities in the HIV-1
reference and patients’ isolated strains
Reference HIV-1 R5 (RU132, SE9173, MP535, BaL), dual
tropic X4/R5 (ARV-2) and X4 tropic (CBL-4) strains (Table 1)
were challenged with scalar concentrations of SB105-A10 (0.1, 1,
5, 10 and 20 mg/ml) in the activated PBMCs. The higher
concentrations of SB105-A10 (5, 10, and 20 mg/ml) significantly
(p,0.05) decreased the HIV-1 p24 content in the cellular
supernatants at day 7 pi, irrespective of the HIV-1 strain
employed (Figure 3A). Subsequently, eight HIV strains were
isolated and purified from the HIV-positive patients. Four of the
subjects were naı¨ve patients, whereas the remaining four were
patients exhibiting therapeutic failure and resistance against
certain protease and reverse transcriptase inhibitors. These viral
strains were sequenced and characterized for their cellular
tropism. All naı¨ve patients were infected with R5 viral variants,
two of the cART-treated patients were infected with the X4/R5
dual tropic strains, and the remaining two of the cART-treated
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patients harboured X4 strains (Table 1). The activated PBMCs
were challenged with these HIV-1 isolated from HIV-1 positive
patients. Similarly to the experiments using HIV-1 reference
strains, the higher concentrations of SB105-A10 (5, 10 and 20 mg/
ml; p,0.05) inhibited the viral replication, as demonstrated by the
HIV-1 gag p24 ELISA assay (Figure 3B) at day 7; in contrast,
SB104 did not exhibit any significant anti-retroviral effects (data
not shown). The determination of the IC50 yielded values between
1.26 (0.27 mM) and 2.1 mg/ml (0.44 mM) among all the tested
reference and patients’ isolated HIV-1 strains.
Analysis of the inhibitory mechanism of SB105-A10
To determine the stage of the viral replication cycle at which
SB105-A10 interferes with the infection, time-binding assays
(Figure 4 A-C) were performed using activated PBMCs that were
challenged with either HIV-1IIIb or HIV-1ada.
In the ‘‘attachment assay’’ (Figure 4A), SB105-A10 was pre-
incubated with either HIV-1IIIb or HIV-1ada strains for 1 hour at
4uC, and this mixture was added to the activated PBMCs and
incubated for 1 hour at 4uC. This protocol facilitated the eventual
attachment of the virus to the cell membrane but did not allow for
viral entry. After washes with PBS, the activated PBMCs were
shifted to a temperature of 37uC, and the infection was allowed to
proceed. The analysis of the HIV-1 p24 protein content, in the cell
culture supernatants at day 4 pi, demonstrated a strong
neutralizing effect on infections of HIV-1 strains (Figure 4D)
thus indicating that SB105-A10 might act on the viral attachment
to the cell membranes of the activated PBMCs.
In the ‘‘pre-attachment assay,’’ (Figure 4B) the activated
PBMCs were treated with SB105-A10 for 1 hours at 4uC to allow
for interaction of the dendrimer with the cell surface. After several
washes, the activated PBMCs were incubated with HIV-1IIIb or
HIV-1ada for 1 hour at 4uC, washed, and shifted to a temperature
of 37uC. The analysis revealed that, at day 4 pi, and under these
experimental conditions, SB105-A10 consistently inhibited the
infections by both HIV-1 strains (Figure 4D), indicating that the
activity of the dendrimer might also depend on its interaction with
the PBMC membrane surface.
The ‘‘post-attachment assay’’ (Figure 4C) was performed to
evaluate whether SB105-A10 could also prevent infection by the
cell-bound virus. The activated PBMCs were incubated with
either HIV-1IIIb or HIV-1ada for 1 hour at 37uC and were
Figure 2. SB105-A10 inhibits HIV-1IIIb and HIV-1ada replication in activated PBMCs. HIV-1IIIb and HIV-1ada were pre-incubated for 1 hours at
37uC with different concentrations (0, 0.1, 1, 5, 10 and 20 mg/ml) of SB105-A10 (A) or SB104 (B) and challenged with activated PBMCs for 2 hours at
37uC. HIV replication was monitored by HIV-1 p24 ELISA and values were determined from cell culture supernatants at day 7 pi. Data were expressed
as the means6 standard deviations (6SD) of HIV-1 gag p24 amount relative to untreated controls (set to 100%). Three experiments in duplicate were
performed. The last two panels (C and D) show that the two dendrimers are not toxic for PBMCs at concentrations tested as documented by trypan
blue technique. Data were expressed as the means (6SD) of viable cells relative to untreated controls (set to 100%) obtained from three independent
experiments in duplicate. * p,0.05.
doi:10.1371/journal.pone.0076482.g002
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repeatedly washed to remove the unbound virus. Subsequently,
SB105-A10 was added to activated PBMCs, and HIV-1 p24 was
analyzed at day 4 pi. The inhibition of the HIV-1 infection was
not detected by this experimental approach, suggesting that the
antiviral effect of SB105-A10 might be related to the interference
of HIV adsorption and/or entry (Figure 4D).
SB105-A10 interacts with HIV envelope proteins
We also investigated the possibility that at least some of the
antiviral effects might be related to a direct interaction between
the HIV particles and SB105-A10. Either HIV-1IIIb or HIV-1ada
was incubated with 20 mg/ml (4.2 mM) of SB105-A10 for 1 hour
at 4uC or 37uC. Following incubation, these mixtures were diluted
50-fold in a medium to reduce the concentration of dendrimer to
below the concentration capable of preventing the HIV infection;
the diluted mixtures were subsequently added to the activated
PBMCs. The analysis of HIV-1 p24 revealed that SB105-A10
significantly reduced the level of HIV-1 infection, suggesting the
direct activity of SB105-A10 on the virion structures (Figure 5).
To substantiate the hypothesis that SB105-A10 inhibits the HIV
infection by sequestering the virus in the extracellular environ-
ment, we investigated the dendrimer capacity to bind HIV-1 gp41
and/or gp120. To this end, SB105-A10 was immobilized onto a
SPR sensorchip, and evaluated for its capacity to bind the two
viral proteins when injected in the fluidic system of a BIAcore X-
100 apparatus. As displayed in Figure 6 (left panels), the
ectodomain of gp41 (amino acids 546–682) and full-lenght
gp120 interacted with SB105-A10. The specificity of the bindings
was proven by the observations that: i) both the HIV proteins did
not bind to a control surface containing only streptavidin; ii) one
eukaryotic protein (BSA) and one glycosylated plant protein (SNA)
poorly bound the SB105-A10 surface (less than 5 RU and 34 RU,
respectively) when injected at 300 nM in the same experimental
conditions used for the HIV proteins (data not shown). Dose
response experiments allowed us to generate saturation curves
(Figure 6, right panels), from which dissociation constant (Kd)
values for the two interactions were calculated. In detail, SB105-
A10 binds to gp41 with an affinity that is 10 times higher than that
for gp120 (Kd equal to 3.9 nM and 46 nM, respectively). These
results suggest that the dendrimer might interact with the viral
envelope, most likely altering the virus attachment and entry.
SB105-A10 binds to heparan sulfates (HS) on activated
PBMC membranes
In addition to the direct activity of SB105-A10 on the envelope
glycoproteins, the pre-attachment assay indicated that the
Figure 3. SB105-A10 treatment inhibits the HIV replication of HIV-1 reference strains and isolates from HIV-1 positive pateints.
Different concentrations (0, 0.1, 1, 5, 10 and 20 mg/ml) of SB105-A10 were added to HIV-1 reference (A) and isolated (B) strains (100 pg/ml p24) for
1 hours at 37uC and then added to activated PBMCs. After two hours, several PBS washings were carried out and p24 determination was performed
at day 7. Significant decreases of HIV-1 p24 amount were detected in infected samples treated with 5, 10 and 20 mg/ml of SB105-A10 with respect to
the untreated controls. Data were expressed as the means (6SD) of HIV-1 gag p24 amount relative to untreated controls (set to 100%) obtained from
three independent experiments in duplicate. * p,0.05.
doi:10.1371/journal.pone.0076482.g003
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dendrimer might inhibit HIV infection through direct binding
with molecular targets on the cell membrane. Moreover, the
effects of SB105-A10 on the replication of viruses such as HSV,
HPV, RSV and HCMV have demonstrated that this molecule
binds to HSPGs [39–41]. Because HSPGs play an important role
in HIV adsorption and entry, we evaluated whether the binding
between SB105-A10 and HSPGs was also detectable in activated
PBMCs. A flow cytometry analysis performed using increasing
concentrations of the dendrimer (Figure 7), yielded a net
increased fluorescence following the FITC-SB105-A10 exposure
with a binding saturation at 25 mg/ml (5.3 mM). This interaction
was partially inhibited by pre-treatment with heparinase III, which
cleaved the HSPGs and significantly decreased, but did not
eliminate, the positive signal. Moreover, the activated PBMCs
treated with FITC-SB105-A10 and further washed with 2M NaCl,
which is a treatment that removes cationic peptides from HSPGs
in the cell membrane [44], displayed decreased fluorescence, as
measured by flow cytometry; however, the binding of FITC-
SB105-A10 with HSPGs was not abolished, thus suggesting that
the dendrimer might also recognize additional receptors on the
cell surface.
SB105-A10 inhibits the HIV-1 infection of cervicovaginal
tissues
To investigate the possible use of SB105-A10 as a microbicide,
we also examined its role in preventing the HIV-1 infection, using
a biologically organotypic model of cervicovaginal epithelial tissue.
To determine whether SB105-A10 acts as an antiretroviral agent
in vaginal tissues, cervico-vaginal samples were infected apically by
HIV-1ada (100 ng HIV-1 p24/tissue) either with or without the
dendrimer (2 or 10 mg/tissue) and were incubated for 24 hours;
subsequently, the HIV-1 proviral DNA levels were determined by
quantitative real-time PCR at day 4 pi using two oligonucleotide
pairs specific for HIV-1 gag and pol genes. The samples that were
treated with SB105-A10 exhibited approximately 10-fold decrease
in their viral DNA burden compared with the untreated HIV-1-
infected vaginal tissue, suggesting that SB105-A10 inhibits the
HIV-1 infection of a biologically relevant human cervicovaginal
tissue model (Figure 8). Because the EpiVaginal tissue is ideally
suited to predict the vaginal toxicity of novel microbicides we also
evaluated the irritation and inflammatory potential of SB105-A10.
Briefly, 100 mg/ml (21 mM) of SB105-A10 was applied to the
apical surface at the air-tissue interface for 1, 4, and 18 hours at
37uC, and the tissues were subsequently analyzed for (i) the
Figure 4. Investigation of SB105-A10-related antiviral mechanisms in activated PBMCs infected by HIV-1IIIb or HIV-1ada strains.
Attachment, pre-attachment and post-attachment assays were carried out as described in panel A, B and C respectively. Significant decreases of HIV-
1 gag p24 in the cellular supernatants were detected at day 4 pi, in SB105-A10-treated samples with respect to untreated controls in pre-attachment
and attachment assays (panel D). Data were expressed as the means (6SD) of HIV-1 gag p24 amount relative to untreated controls (set to 100%)
obtained from three independent experiments in duplicate. *p,0.05.
doi:10.1371/journal.pone.0076482.g004
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reduction of tetrazolium salt (MTT), to study the metabolic
activity of the living cells; (ii) LDH release, to measure the
accumulation of dead cells; and (iii) the release of IL-1 a, to
evaluate the inflammatory activation of cells (see the Materials and
Methods for further details). As reported in Table 2, SB105-A10
was not cytotoxic, and the time required to reduce tissue viability
to 50% (ET50) was greater than 18 hours. No significant difference
in the release of the cytoplasmic enzyme LDH was observed
between SB105-A10-treated and untreated tissues. Finally, our
results indicate that SB105-A10-exposed human-derived vaginal
epithelial cells do not exhibit significant differences in the levels of
the pro-inflammatory cytokine IL-1a, (Table 2), compared with
the untreated samples. Similar results were obtained when a 10-
fold higher dose of SB105-A10 was applied to the EpiVaginal
Figure 5. Pre-incubation of SB105-A10 either with HIV-1IIIb or HIV-1ada strains inhibits the viral infectivity in dilution assay. HIV-1
strains were incubated for 1 hour at 37uC with SB105-A10 (20 mg/ml; 4.2 mM). Following this incubation the samples were diluted 50-fold to reduce
dendrimer concentrations to a level below that at which SB105-A10 significantly inhibits HIV replication and challenged with activated PBMCs.
Significant decrease of HIV-1 p24 amount was detectable at day 4 pi. Data were expressed as the means (6SD) of HIV-1 p24 amount relative to
untreated controls (set to 100%) for each HIV-1 strain obtained from three independent experiments in duplicate. * p,0.05.
doi:10.1371/journal.pone.0076482.g005
Figure 6. SPR analysis of the interaction of SB105-A10 with HIV-1 gp41 and gp120 proteins. Left panels: blank-subtracted sensorgrams
showing the binding of gp41 ectodomain (aminoacids 546–682; 10 nM) and full-lenght recombinant gp120 glycoprotein (100 nM) to the sensorchips
containing streptavidin and biotinylated SB105-A10 (straight line) or streptavidin alone (dotted line). Right panels: saturation curves of the binding of
gp41 and gp120 to immobilized SB105-A10 peptide. The saturation curves were obtained using the values of RU bound at equilibrium after the
injection of different concentrations (0.61, 1.25, 2.5, 5.0, 10 nM for gp41 and 12.5, 25, 50, 100 nM, for gp120). The x2 values of the fitting of the
saturation curves were equal to 2.6 and 4.3 for gp41 and gp120 respectively.
doi:10.1371/journal.pone.0076482.g006
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tissue (data not shown). Overall, these results indicate that SB105-
A10 is neither toxic nor pro-inflammatory to the vaginal mucosa.
Discussion
We aimed to determine whether the SB105-A10 dendrimer
inhibits HIV-1 infection in activated PBMCs. The present study
mainly demonstrated that: i) SB105-A10 inhibited HIV replication
of all of the tested reference and HIV-1 strains that were isolated
from HIV-positive patients in activated PBMCs, as indicated by
the HIV-1 p24 protein ELISA assay in the cell culture
supernatants; ii) SB105-A10 interfered with the attachment/entry
of HIV-1 by multiple mechanisms targeting cell membrane
HSPGs and HIV virions; in particular, SB105-A10 bound gp41
and gp120 as revealed by the SPR analysis; and iii) SB105-A10
also inhibited the HIV infection in a biologically organotypic
model of cervicovaginal epithelial tissue.
The antiviral effect of SB105-A10 was tested on a wide range of
R5, X4 and dual tropic R5/X4 HIV-1 strains, and a significant
and reliable decrease of HIV-1 p24 protein amount was detected
by the HIV-1 p24 ELISA assay in supernatants of the activated
PBMCs. Interestingly, among the HIV-1 strains that were
challenged by SB105-A10, it was observed that this dendrimer
was also able to suppress HIV-1 strains that were isolated from
HIV-1 naı¨ve patients and HIV-1-positive patients infected by
strains resistant to certain reverse transcriptase and protease
inhibitors. Hence, SB105-A10 exhibited an antiviral effect that
was independent of the HIV strain tropism, with comparable IC50
values observed in the R5 and X4 strains.
Analysis of the antiretroviral mechanisms indicated that the
dendrimer might target an early event during the viral replication.
The pre-attachment and attachment assays revealed that SB105-
A10 effectively inhibited the HIV infection, whereas a significant
p24 protein decrease was not detected following the post-
attachment procedure. These observations suggest that SB105-
A10 may prevent HIV-1 infection by acting on the first phases of
the viral replication cycle, which are most likely represented by
viral attachment/entry. The initial interaction between HIV and
the cell membrane is facilitated by interactions between the
positively charged domains on gp120 and the negatively charged
heparan-sulfated proteoglycans on the target cell membrane or by
interactions with cell membrane lectin-binding proteins such as
Figure 7. Flow cytometry analysis of binding between SB105-A10 and heparan sulphates. Typical experiments were shown. (A), Different
concentrations of FITC-conjugated SB105-A10 (from 0 to 250 mg/ml) were assayed for 1 hour at 4uC on activated PBMCs (56106/ml). The saturation
was achieved at 25 mg/ml. (B), Activated PBMCs (56106/ml) were treated with 25 mg/ml of FITC-conjugated SB105-A10 for 1 hour at 4uC and then
washed with PBS containing 2 M NaCl, a treatment known to remove cationic polypeptides from cell surface HSPGs. (C), Activated PBMCs (56106/ml)
were incubated with heparinase III for 2 h at 37uC or left untreated before the binding assay with 25 mg/ml of FITC-conjugated SB105-A10. Both
heparinase III and 2 M NaCl treatments reduce but not abolish the specific fluorescence signal suggesting an interaction between SB105-A10 and cell
membrane that is not related to HSPGs.
doi:10.1371/journal.pone.0076482.g007
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DC-SIGN [47–49]. Protein gp120 then binds to CD4, and this
interaction induces a conformational shift of the gp120 structure
that causes the formation of a bridging sheet with the exposure of
the V1/V2 and V3 loop [50–52]. These steric changes allow for
the binding of gp120 to the CXCR4 and CCR5 co-receptors and
the fusion of the gp41 ectodomain with the cell membrane
[53,54]. The fusion is determined via the formation of a six-helical
bundle in which three gp41 N-terminal heptad repeats form a
trimeric inner core and three C-terminal heptad repeats are
packed in an antiparallel manner against the inner trimer [55].
The free energy that is released by the bundle formation leads to
the juxtaposition and subsequent fusion of the viral and target cell
membranes [56]. The SPR assay demonstrated that SB105-A10
bound at a high affinity to the HIV envelope protein gp41 and, to
lesser extent, gp120. It is conceivable that binding of SB105-A10
to the two viral envelope glycoproteins may determine, through
the dendrimer’s multivalency, an alteration in the correct steric
interaction between the viral envelope glycoproteins and the
cellular receptors thereby inhibiting HIV-1 entry into activated
PBMCs. Interestingly, the SPR indicated that the high-affinity
binding between SB105-A10 and gp41 is localized to the
ectodomain of gp41. SB105-A10 binds the ectodomain of gp41
in a region that encompasses the amino acids between 546 and
682. This domain is strongly involved in the formation of the
bundle and plays a pivotal role in the fusion between the virus and
the cell surface [57,58]. SB105-A10 might then be considered a
factor that binds to both the gp41 and the gp120 envelope binding
glycoproteins. It is noteworthy that several anti-HIV agents bind
to the gp41 or gp120 glycoproteins. Among the agents that target
gp41, T-20 is the most important and is used in antiretroviral
therapy [59]. T-20 is derived from gp41 ectodomain sequences
and prevents formation of the viral gp41 bundle, as well as the
fusion and entry of HIV-1 into the target cell [60–61], by forming
heterotrimers with its counterparts in gp41. The synthesis and
utilization of T-20 as an antiretroviral has promoted the
development of similar drugs that inhibit gp41 fusion by
competitive mechanisms; in fact, C52L and HR212 suppress
formation of the viral gp41 bundle and viral entry [62–63].
Conversely, other drugs have non-competitive mechanisms: RC-
101, which is a cationic derivate of the defensin theta, binds
directly to gp41 and suppresses the HIV infection by inhibiting
HIV entry [64–65]. Several molecules bind to gp120, thereby
interfering with the interaction between gp120/CD4 and/or the
gp120/co-receptors. Lectins, polyanions, agents targeting the
CD4-binding site of gp120 and antibodies have been described
and employed in some trials [9,48,66–68]. Mannose-rich glycans
are present on the envelope structure and are the target of several
anti-HIV molecules, such as the lectins [9]. Cyanovirin, Griffithsia
are two of the substances, with anti-HIV characteristics, that bind
to gp120 glycosylated structures and inhibit the entry of the R5
and X4 HIV-1 isolates [69,70]. Moreover, polyanions such as
PRO 2000, PC-515 and cellulose sulfate recognize positively
charged regions on gp120 [71,72]. PRO-2000 displays a wide
range of activity by recognizing gp120, CD4 and co-receptors
showing antiviral effects, especially against X4 tropic strains [73].
Polyanions represent a classical group of HIV-entry inhibitors;
indeed two dendrimers with negatively charged branching arms
(namely SPL7103 and SPL 7115) have demonstrated gp120-
binding activities [74]. Interestingly, experiments on non human
primates indicated that the intravaginally treatment of macaques
by 3-5% w/w SPL7013 gel effectively prevented the vaginal
transmission of SHIV89.6 chimeric virus strain [37]. SB105-A10
is a peptide-derived dendrimer that originates from the M6
prototype, which is a tetra-branched dendrimer [38]. This
molecule contains a lysine core that tethers four 9-mer peptide
chains [38] and exhibits a polycationic sequence of basic amino
acids in the branching arms, in contrast with the polyanionic
stretch of SPL7103 and SPL7115 [74]. The antiviral effectiveness
of SB105-A10 is related to this sequence of basic aminoacids. In
fact, the dendrimer SB104, which has a different sequence, did not
show any significant anti-viral activity. Polycation substances exert
opposite effects on the HIV infection; however, recently, defensin,
defensin-derived (RC-101) cationic peptides and other dendrimers
(polycationic viologen) have demonstrated reliable anti-HIV
effects via binding to gp41 and CXCR4, respectively
[64,65,75,76]. SB105-A10 exhibits a more complex antiretroviral
activity; in fact, the SB105-A10 administration prior to an HIV
challenge yields inhibitory effects on HIV replication suggesting an
additional cell-membrane target. As demonstrated recently, the
basic amino acids residues of SB105-A10 bind to the negatively
charged sulfated/carboxyl groups of the heparan sulfate chain of
HSPGs in several cell models and inhibit the attachment/entry of
several viruses, such as HSV-1, HSV-2, HPV, HCMV, RSV and
Ebola virus [39–41,77]. HSPGs are cell membrane receptors
composed of a core protein linked to sulfated glycosaminoglycans
(GAGs). GAGs are long, negatively charged polysaccharides that
Figure 8. Determination of HIV-1 proviral DNA content in
Epivaginal tissue infected by HIV-1ada. EpiVaginal
TM tissues were
challenged with HIV-1ada (25 ng/ml) plus the SB105-A10 dendrimer (2
or 10 mg/tissue) for 24 hours, and total DNA was extracted and purified
from vaginal tissues at day 4 pi. HIV-1 DNA burden was determined by
SYBR Green-based quantitative real time PCR using either HIV-1 gag or
pol gene-specific primer pairs [45,46]. Data are expressed as the fold
decrease (6SD) of the DNA proviral content in dendrimer-treated cell
culture with respect to DNA proviral amount determined in untreated
cell cultures, obtained from two independent experiments in quadru-
plicate.
doi:10.1371/journal.pone.0076482.g008
Table 2. Evaluation of the irritation potential of 100 mg/ml of
SB105-A10 (21.3 mM) on the EpiVaginal tissue model.
Viability LDH Release IL-1 a Release
(%) (Abs) (pg/ml)
Untreated (1 hour) 100 0.960.1 13.462.9
SB105-A10 (1 hour) 81.8 0.960.1 11.764.5
Untreated (4 hours) 100 0.760.1 8.362.6
SB105-A10 (4 hours) 100.9 0.960.01 16.663.5
Untreated (18 hours) 100 1.360.1 33.264.2
SB105-A10 (18 hours) 78.5 1.160.01 24.563.0
doi:10.1371/journal.pone.0076482.t002
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are linked to HS and that are widely detectable on cell membranes
of various cell types [78]. HSPGs are involved in the initial
attachment of many viruses to the cell surface [79]. Examples of
these viruses include Herpesviridae (HSV, HCMV), Papovaviridae
(HPV), Flaviviridae (HCV, dengue), Paramyxoviridae (RSV) and
Retroviridae (HIV, HTLV) [80–86]. HIV gp120 recognizes HS
through V3 loop that facilitates the attachment to the host cell and
subsequent infection [86–89]. Interestingly, the removal of HS or
the use of heparin as a competing molecule reduced both HIV
attachment and infection in several cell models such as CD4+
HeLa, T-cell lines and macrophages [90–92]. Moreover, HS are
involved in the gp41-mediated fusion of HIV with the cell
membrane and play an important role in the HIV infection of
CD4-negative cell models (such as CD4 negative brain endothelial
cells) by affecting HIV attachment and entry [93,94]. SB105-A10
consistently binds to HS in activated PBMCs. Interestingly, the
activation of PBMCs by PHA induces a strong increase in heparan
sulfates exposed on the cell membrane compared with unactivated
PBMCs [85]. SB105-A10 binds to HS on the cell membrane of
activated PBMCs although the treatment with either heparinase or
NaCl did not completely inhibit the binding of SB105-A10 to the
cell membrane, suggesting that the dendrimer may also interact-
with additional cellular targets.
As reported above, SB105-A10 exhibits a broad antiviral
activity against several viruses, as has been demonstrated for
another dendrimer (SPL7013) that strongly inhibits the entry of
HIV, HSV-1 and HSV-2 [74]. SB105-A10 exerts its antiviral
activity against certain viruses that are transmitted by sexual
intercourse; these viruses include HPV and HSV, which recognize
cell targets through the viral anti-receptor binding of HS [39–41].
This characteristic indicates that SB105-A10 is a good candidate
for use as a broad-spectrum microbicide that counteracts not only
HIV but also HPV and HSV. It is noteworthy that the presence of
inflammatory and genital lesions due to HSV and HPV infections
facilitates the HIV infection transmission [9]. The microbicides
are compounds that would protect the user from sexually
transmitted infections when applied topically to mucosal structures
such as the vagina and rectum. This topical prevention strategy
represents a prophylactic approach that may be employed
especially in individuals who do not use condoms during sexual
intercourse. Interestingly, different classes of microbicides have
been proposed for prevention of the HIV infection. These
compounds act on various stages of the HIV mucosal infection;
in fact, agents that disrupt the free virus, blocking cell capture, or
target the viral structure or cell receptors or specific viral
replication stages have been widely described as microbicides
although the majority of these compounds have not passed the
trials [21]. However, TDF administered orally or by gel [23] has
yielded effective results; however, certain studies have not
reproduced these results most likely because of low levels of
patient compliance [28,29]. Novel evidence has also supported
the use of other antiretrovirals, including combinations (TDF and
emtricitabine) used in cART for oral prophylaxis, and promising
results have been obtained from the initial analyses [95,96].
SB105-A10 was challenged with R5 tropic HIV-1ada strain in
human cervico-vaginal tissues [64]. The analysis of SB105-A10
antiviral activity against the R5 tropic HIV-1 strains is pivotal
because the HIV-1 R5 strains are predominantly involved in the
sexual transmission of HIV. The quantitative analysis of HIV-1
proviral DNA by real-time PCR demonstrated a strong decrease
of the HIV-1 DNA content in the SB105-A10-treated samples
compared with the untreated samples. In addition, SB105-A10
does not elicit an inflammatory response or cytotoxicity in this
tissue model thus validating the potential use of this molecule as a
topical microbicide. However, toxicity and efficacy studies
conducted using non-human primate models must be performed
to validate SB105-A10 as a topical microbicide candidate for
prevention of the heterosexual transmission of HIV-1 and other
specific sexually transmitted viruses.
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